Newborn screening is a highly recommended approach to identify metabolic or congenital risks in infants, crucially contributing to minimizing long-term impairments and promoting the healthy development of newborns.
Newborn screening is a highly recommended approach to identify metabolic or congenital risks in infants, crucially contributing to minimizing long-term impairments and promoting the healthy development of newborns.
Mylab will produce tests based on fluorometric chemical quantification of substances extracted from dried blood spots as part of this initiative. The advantages of this method include faster results with just a few drops of blood, enabling early detection of genetic disorders, and facilitating prompt treatment.
In July 2023, Mylab has been licensed to manufacture biochemical detection tests for G6PD, Galactose, and Phenylalanine. These tests will play a significant role in newborn screening, enhancing the healthcare system's ability to proactively address potential health issues in newborn babies.
Mylab launched Mybox+ diagnostic device with a range of Dry-LIA tests including Thyroid panel (T-3, T-4, TSH), Cardiac marker (Troponin), and biomarker (CRP, D-Dimer).
Mylab launched Mybox+ diagnostic device with a range of Dry-LIA tests including Thyroid panel (T-3, T-4, TSH), Cardiac marker (Troponin), and biomarker (CRP, D-Dimer).
MyBox+ represents a portable device equipped with optical AI engines, offering accurate and rapid quantitative and qualitative results for clinical samples. With the capability to conduct tests for over 30 diseases, this invaluable diagnostic tool can be effortlessly set up in small labs and centers, streamlining healthcare processes and facilitating prompt and reliable patient care.
Kudos to team Mylab for their sincere efforts & booming launch of MyBox+.
Dr. Minal Dakhave and her colleagues made a significant contribution to the field of fast-track diagnostics by publishing a journal article focused on the Fast-track Diagnostic Requisite for Sepsis and its Antimicrobial Resistance in Low Resource Settings.
Dr. Minal Dakhave and her colleagues made a significant contribution to the field of fast-track diagnostics by publishing a journal article focused on the Fast-track Diagnostic Requisite for Sepsis and its Antimicrobial Resistance in Low Resource Settings.
The article, featured in the indexed Journal of Virology and Vaccine Development, delves into the use of real-time PCR tests and their commercial viability in detecting bacterial and viral resistance. Additionally, the research highlights the importance of innovative, compact, and cost-effective Point-of-care devices for more effective strategies related to antibiotic treatment and the quality of healthcare services in developing countries.
Article Citation: Dakhave M, Khaire A. Fast Track Diagnostic Requisite for Sepsis, and its Antimicrobial Resistance in Low Resource Settings: A Step Towards Antimicrobial Stewardship. J Virol Vaccine Dev. (2023);3(1): 1-4.
The foundation of devising suitable treatment and prevention strategies for managing disease burden lies in disease monitoring. In this context, on July 26, 2023, Dr. Minal Dakhave delivered a talk on ‘Emerging Technologies in Point-of-Care Diagnostics’ during a high-end workshop sponsored by SERB (Science and Engineering Research Board).
The foundation of devising suitable treatment and prevention strategies for managing disease burden lies in disease monitoring. In this context, on July 26, 2023, Dr. Minal Dakhave delivered a talk on ‘Emerging Technologies in Point-of-Care Diagnostics’ during a high-end workshop sponsored by SERB (Science and Engineering Research Board).
During her expert presentation, Dr. Dakhave shed light on the continuous evolution of point-of-care diagnostics through innovative technologies. She also emphasized its vital role in disease monitoring. The workshop brought together numerous experts and stakeholders from the field of molecular medicine in India, creating an enriching and collaborative environment.
We commend Dr. Dakhave for delivering a thought-provoking & inspiring talk on such a complex topic.
Renowned for recognizing innovative ideas and solutions in the AMR domain, this year, the C-CAMP AMR Quest centred around ESKAPE pathogens and their development and commercialization.
Renowned for recognizing innovative ideas and solutions in the AMR domain, this year, the C-CAMP AMR Quest centred around ESKAPE pathogens and their development and commercialization.
A total of 140 applications were submitted by startups and individual innovators. Following a rigorous competition, only seven applicants in the Therapeutics and Diagnostics categories advanced to the Final Grand Jury Presentation. Among these exceptional finalists, Dr. Shrikant Pawar, Mylab's GM (R&D), Serology & Microbiome, emerged as the winner of the C-CAMP AMR Quest 2023.
Dr. Pawar's focus was on Vancomycin resistance detection in Enterococcus spp, earning him multiple rewards in mentorship programs of science, business, regulatory, patent law, and fundraising guidance. Additionally, he received investment opportunities in startups and full sponsorship to participate in prestigious International Conferences.
The recognition and accolades received by Dr. Pawar underscore his commitment to fostering groundbreaking research and innovation in the field of AMR, contributing significantly to the advancement of science and healthcare.
We applaud Dr. Shrikant Pawar for this enormous achievement & wish him continued success in future endeavours.
At the beginning of July 2023, our Serology Department, in the IDEA competition as ‘Mylab OncoPlayers’ during the ‘3 DAYS WORKSHOP & HANDS ON TRAINING ON PAPER-BASED MICROFLUIDICS AND LATERAL FLOW DEVICES’ conducted by Department of Medical Devices, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad.
Embodying the spirit of the phrase “Many Hands Make Work Lighter,” Mylab Oncoplayers won the Winning Badge, Certificates & Souvenirs for their collaborative presentation of the ingenious concept, “Microfluidic-based Detection of HPV.” Their teamwork and resourcefulness were key factors that impressed the judges and earned them well-deserved accolades.
Following the remarkable success of HPV detection kits for Type 16 & 18 and the extended monsoon fever panel, Mylab will begin the production of HPV High-risk Detection Kits and Respiratory Viral & Bacterial panels.
Following the remarkable success of HPV detection kits for Type 16 & 18 and the extended monsoon fever panel, Mylab will begin the production of HPV High-risk Detection Kits and Respiratory Viral & Bacterial panels.
The HPV High-risk Detection Kit is a multiplex real-time PCR assay designed to qualitatively detect high-risk HPV types and differentiate them from HPV 16 & 18 genotypes. These advanced kits offer rapid testing solutions, facilitating quick and accurate diagnosis, thereby playing a vital role in mass screening initiatives.
Additionally, Mylab's Respiratory panel, based on real-time PCR technology, can simultaneously detect, and differentiate multiple viral and bacterial respiratory organisms. This comprehensive and efficient solution serves as a one-stop, fast, and accurate method for detecting all respiratory system-related viruses and bacteria.
Mylab has introduced a range of Dry Luminescence Immunoassay based tests including hCG, Dengue IgG/IgM, HbA1c & Thyroid panel to U-Albumin & Vitamin D tests.
Mylab has introduced a range of Dry Luminescence Immunoassay based tests including hCG, Dengue IgG/IgM, HbA1c & Thyroid panel to U-Albumin & Vitamin D tests.
Additionally, Mylab received approval to manufacture FSH-based tests in the women's health segment, along with urine analysis & Dengue antigen-antibody test.